GE

341.25

+0.31%↑

CAT

742.76

-1.32%↓

RTX

201.83

+2.5%↑

GEV.US

872.85

-0.37%↓

BA

227.35

-0.8%↓

GE

341.25

+0.31%↑

CAT

742.76

-1.32%↓

RTX

201.83

+2.5%↑

GEV.US

872.85

-0.37%↓

BA

227.35

-0.8%↓

GE

341.25

+0.31%↑

CAT

742.76

-1.32%↓

RTX

201.83

+2.5%↑

GEV.US

872.85

-0.37%↓

BA

227.35

-0.8%↓

GE

341.25

+0.31%↑

CAT

742.76

-1.32%↓

RTX

201.83

+2.5%↑

GEV.US

872.85

-0.37%↓

BA

227.35

-0.8%↓

GE

341.25

+0.31%↑

CAT

742.76

-1.32%↓

RTX

201.83

+2.5%↑

GEV.US

872.85

-0.37%↓

BA

227.35

-0.8%↓

Ocugen Inc

Затворен

1.81 -2.16

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.79

Максимум

1.81

Ключови измерители

By Trading Economics

Приходи

-5.3M

-20M

Продажби

379K

1.8M

Марж на печалбата

-1,144.463

Служители

95

EBITDA

-4.9M

-18M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+321.43% upside

Дивиденти

By Dow Jones

Следващи печалби

4.03.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

56M

537M

Предишно отваряне

3.97

Предишно затваряне

1.81

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.03.2026 г., 23:35 ч. UTC

Значими събития в новините

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1.03.2026 г., 23:49 ч. UTC

Пазарно говорене
Значими събития в новините

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1.03.2026 г., 23:47 ч. UTC

Пазарно говорене
Значими събития в новините

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1.03.2026 г., 23:41 ч. UTC

Пазарно говорене
Значими събития в новините

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1.03.2026 г., 23:39 ч. UTC

Пазарно говорене
Значими събития в новините

Global Equities Roundup: Market Talk

1.03.2026 г., 23:39 ч. UTC

Пазарно говорене
Значими събития в новините

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1.03.2026 г., 23:36 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1.03.2026 г., 23:24 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

1.03.2026 г., 23:24 ч. UTC

Пазарно говорене

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1.03.2026 г., 23:21 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.03.2026 г., 23:21 ч. UTC

Пазарно говорене

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1.03.2026 г., 23:19 ч. UTC

Значими събития в новините

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1.03.2026 г., 23:17 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1.03.2026 г., 23:14 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1.03.2026 г., 22:55 ч. UTC

Значими събития в новините

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1.03.2026 г., 22:54 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1.03.2026 г., 22:53 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1.03.2026 г., 22:38 ч. UTC

Пазарно говорене
Значими събития в новините

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1.03.2026 г., 22:21 ч. UTC

Печалби

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1.03.2026 г., 22:17 ч. UTC

Пазарно говорене

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1.03.2026 г., 22:13 ч. UTC

Пазарно говорене
Значими събития в новините

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1.03.2026 г., 22:00 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1.03.2026 г., 21:40 ч. UTC

Пазарно говорене
Значими събития в новините

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1.03.2026 г., 21:35 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1.03.2026 г., 21:30 ч. UTC

Пазарно говорене

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1.03.2026 г., 21:27 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1.03.2026 г., 21:19 ч. UTC

Пазарно говорене
Значими събития в новините

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1.03.2026 г., 20:58 ч. UTC

Пазарно говорене
Значими събития в новините

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1.03.2026 г., 20:40 ч. UTC

Пазарно говорене

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1.03.2026 г., 20:24 ч. UTC

Пазарно говорене
Значими събития в новините

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

321.43% нагоре

12-месечна прогноза

Среден 7.67 USD  321.43%

Висок 8 USD

Нисък 7 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

No Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat